Physician profile
Ryan R Lang
NPI 1881957561
$1,525.41
in general payments reported to CMS, 2019-2025
11 companies · $361 in 2025
The $361 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.41 · 2020: $11.30 · 2021: $233 · 2022: $172 · 2023: $314 · 2024: $388 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,062.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $408.10 | 2019-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $305.35 | 2022-2025 | Infuse, Btod |
| Alcon Vision LLC | $273.23 | 2019-2025 | Precision7, Total30 |
| Oyster Point Pharma, INC. | $255.52 | 2023-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Glaukos Corporation | $110.65 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $68.64 | 2019-2021 | |
| Harrow Eye, LLC | $29.77 | 2024 | Vevye |
| Abbvie INC. | $29.39 | 2022-2023 | |
| Lkc Technologies, INC. | $17.53 | 2025 | |
| Allergan, INC. | $17.21 | 2021 | |
| Biotissue Holdings INC. | $10.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Lang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.